Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 17/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25970986 | 0.93 | MAPK1 (0.54) | MAPK1BRD4 | |
| SCHEMBL25970936 | 0.92 | MAPK1 (0.61) | MAPK1 | |
| SCHEMBL25970994 | 0.92 | MAPK1 (0.54) | MAPK1BRD4 | |
| SCHEMBL25970921 | 0.92 | MAPK1 (0.57) | MAPK1BRD4 | |
| SCHEMBL21558019 | 0.91 | MAPK1 (0.59) | MAPK1STAT6PIK3CDPIK3CAPIK3CB | |
| SCHEMBL25971022 | 0.91 | MAPK1 (0.72) | MAPK1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25971015 | 0.89 | MAPK1 (0.52) | MAPK1 | |
| SCHEMBL25970899 | 0.88 | MAPK1 (0.70) | MAPK1PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL25971005 | 0.87 | MAPK1 (0.49) | MAPK1 | |
| SCHEMBL21557656 | 0.86 | MAPK1 (0.58) | MAPK1PIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885STAT6 697/4885PIK3CD 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.